% | $
Quotes you view appear here for quick access.

CryoLife Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thebuckeye777 thebuckeye777 Aug 24, 2012 12:45 PM Flag

    CRY as a Buy-Out Candidate:

    The main product besides Perclot and Biofoam, I see getting FDA approval is the decelluzied aorta heart valve using Synergraft technology. In 2008 when CRY got the pulmonary heart valve approved using the same technology, the stock went from the 6s to 16.50 in about 6 months. Heart surgeons had a waiting list of kids lined up for surgery. ( Now with a defective aorta heart valve one of the solutions is named after Doctor Ross whereby the defective aorta is replaced with the patient's own pulmonary heart valve and then a new pulmonary valve is inserted using the Synergraft technology!) This tissue product has a 60% gross margin last I heard. It's hard for me to believe that the pulmonary heart valve was approved by FDA more than 4 years ago with great success and arota still hasn't been approved.
    Mgt. has stated that they are working on getting Perclot approved in Canada and Brazil. That could happen within the next year. To me that is a big thing because the worldwide market for Perclot is much bigger than worldwide market for Bioglue. Every hospital needs a product like that whereas only hospitals that are doing more critical life and death surgeries like heart surgeries need Bioglue.
    I don't have a time line for FDA approval of Biofoam but think mgt. is working on it. My guess is Biofoam is a great product because last I heard 3 hospitals in Germany are using it. I think the Germans are by far the highest quality guys in Europe so their acceptence of Biofoam gives me confidence in the quality of the product. The worldwide market for Biofoam is much smaller than either Bioglue or Perclot. However approval of all three products would give CRY considerable marketing power helping each products sales in my opinion. CRY could say we have the highest quality product in each product category!
    I think there are also oppotunities to expand the sales and margins on the aquisitions of Cardiogenesis and Hemophere.
    This is my own personal opinion. Do your own homework.

15.95-0.11(-0.68%)Aug 31 4:02 PMEDT